PE20081251A1 - Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico - Google Patents

Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico

Info

Publication number
PE20081251A1
PE20081251A1 PE2007001720A PE2007001720A PE20081251A1 PE 20081251 A1 PE20081251 A1 PE 20081251A1 PE 2007001720 A PE2007001720 A PE 2007001720A PE 2007001720 A PE2007001720 A PE 2007001720A PE 20081251 A1 PE20081251 A1 PE 20081251A1
Authority
PE
Peru
Prior art keywords
crystalline forms
tetrafluorophenoxy
alaninyl
terc
oxopentanoic
Prior art date
Application number
PE2007001720A
Other languages
English (en)
Inventor
Stuart Dimmock
Eric Hagen
Jason Hanko
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of PE20081251A1 publication Critical patent/PE20081251A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
    • C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/22—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton having nitrogen atoms of amino groups bound to the carbon skeleton of the acid part, further acylated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/52—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

SE REFIERE A FORMAS CRISTALINAS DEL ACIDO (3S)-3-[N-(N'-(2-TERC-BUTILFENIL)OXAMIL)ALANINIL]AMINO-5-(2',3',5',6'-TETRAFLUOROFENOXI)-4-OXOPENTANOICO TALES COMO LA FORMA CRISTALINA I CUYO PATRON DE DIFRACCION DE POLVO DE RAYOS X POSEE LOS SIGUIENTES PICOS EXPRESADOS EN GRADOS 2O: 7,7; 14,1; 21,4; 26,6 Y 29,4; LA FORMA CRISTALINA II CUYO PATRON DE DIFRACCION DE POLVO DE RAYOS X POSEE LOS SIGUIENTES PICOS EXPRESADOS EN GRADOS 2O: 14,5; 17,3; 22,5; 25,0 Y 26,8. SE REFIERE TAMBIEN A COMPOSICIONES FARMACEUTICAS DE LAS FORMAS CRISTALINAS LAS CUALES SON UTILES EN EL TRATAMIENTO DE FIBROSIS HEPATICA
PE2007001720A 2006-12-06 2007-12-05 Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico PE20081251A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86874806P 2006-12-06 2006-12-06

Publications (1)

Publication Number Publication Date
PE20081251A1 true PE20081251A1 (es) 2008-09-17

Family

ID=39205161

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007001720A PE20081251A1 (es) 2006-12-06 2007-12-05 Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico

Country Status (23)

Country Link
US (1) US7692038B2 (es)
EP (1) EP2091910B1 (es)
JP (1) JP5495787B2 (es)
KR (1) KR101125932B1 (es)
CN (3) CN101573328B (es)
AR (1) AR064809A1 (es)
AU (1) AU2007330478B2 (es)
CA (1) CA2669849C (es)
CL (1) CL2007003491A1 (es)
DK (1) DK2091910T3 (es)
ES (1) ES2524021T3 (es)
HK (3) HK1138567A1 (es)
HN (1) HN2007000536A (es)
IL (1) IL198732A (es)
MX (1) MX2009006055A (es)
NO (1) NO338908B1 (es)
PA (1) PA8759501A1 (es)
PE (1) PE20081251A1 (es)
PL (1) PL2091910T3 (es)
PT (1) PT2091910E (es)
TW (1) TWI345466B (es)
UY (1) UY30758A1 (es)
WO (1) WO2008068615A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS59494B1 (sr) * 2010-02-12 2019-12-31 Pfizer Soli i polimorfi 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3,4,5-tetrahidro-6h-azepino[5,4, 3-cd]indol-6-ona
CN103113405B (zh) * 2012-10-17 2016-03-02 上海日馨生物科技有限公司 苯磷硫胺多晶型体、制备方法及其应用
NZ723859A (en) * 2014-03-14 2023-01-27 Servier Lab Pharmaceutical compositions of therapeutically active compounds and their uses
MX2016014731A (es) 2014-05-12 2017-05-04 Conatus Pharmaceuticals Inc Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa.
EP3191461B1 (en) * 2014-09-08 2021-11-03 Pfizer Inc. Crystalline solid forms of 6-carboxy-2-(3,5-dichlorophenyl)-benzoxazole
NZ772411A (en) 2015-01-30 2022-05-27 Vertex Pharma Crystalline forms of c21h22ci2n4o2
US20180044375A1 (en) 2015-03-06 2018-02-15 Concert Pharmaceuticals, Inc. Deuterated emricasan
CN105017061B (zh) * 2015-07-07 2017-03-29 苏州富士莱医药股份有限公司 一种恩利卡生的合成方法
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
WO2017117478A1 (en) 2015-12-31 2017-07-06 Conatus Pharmaceuticals Inc. Methods of using caspase inhibitors in treatment of liver disease
RU2019113150A (ru) 2016-10-05 2020-11-06 Новартис Аг Комбинация композиций, содержащих агонисты fxr, предназначенная для лечения или предупреждения фиброзирующего, цирротического заболевания или нарушения
WO2018133870A1 (zh) * 2017-01-23 2018-07-26 正大天晴药业集团股份有限公司 作为Caspase抑制剂的联环化合物
WO2018172950A1 (en) * 2017-03-23 2018-09-27 Novartis Ag Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate
JP7295025B2 (ja) * 2017-03-30 2023-06-20 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング （ｓ）－［２－クロロ－４－フルオロ－５－（７－モルホリン－４－イルキナゾリン－４－イル）フェニル］－（６－メトキシ－ピリダジン－３－イル）メタノールの結晶性形態
AR114251A1 (es) * 2018-02-13 2020-08-12 Syngenta Participations Ag Formas cristalinas de n-[2-(2,4-diclorofenil)ciclobutil]-2-(trifluorometl)piridin-3-carboxamida
US11447497B2 (en) 2018-06-29 2022-09-20 Histogen, Inc. (S)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
TW202100506A (zh) 2019-03-07 2021-01-01 美商柯納特斯製藥公司 半胱天冬酶(caspase)抑制劑及其使用方法
CN111351780A (zh) * 2019-12-29 2020-06-30 中船重工（邯郸）派瑞特种气体有限公司 一种三氟甲基磺酰氟电解槽中电解液成分的分析方法
WO2022123062A1 (en) 2020-12-11 2022-06-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Blocking caspase and/or fasl for preventing fatal outcome in covid-19 patients

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0526171B1 (en) * 1991-07-30 1997-03-05 Ajinomoto Co., Inc. Crystals of N-(trans-4-isopropylcyclohexylcarbonyl)-D-phenylalanine and methods for preparing them
ATE157349T1 (de) * 1993-05-12 1997-09-15 Heumann Pharma Gmbh & Co Stabile und kristalline form von bezafibrat
US7053056B2 (en) 1998-07-02 2006-05-30 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6544951B2 (en) * 1998-07-02 2003-04-08 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
US6197750B1 (en) 1998-07-02 2001-03-06 Idun Pharmaceuticals, Inc. C-terminal modified oxamyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
GB9923933D0 (en) * 1999-10-08 1999-12-08 Smithkline Beecham Lab Novel pharmaceutical
DE60225841T2 (de) * 2001-12-11 2009-05-14 Kyorin Pharmaceutical Co., Ltd. Neue stabile kristalle substituierter phenylpropionsäurederivate und verfahren zu deren herstellung
CA2614622A1 (en) * 2005-07-11 2007-01-18 Pfizer Limited New combination of anti-madcam antibody and antifibrotic caspase inhibitor to treat liver fibrosis

Also Published As

Publication number Publication date
WO2008068615A1 (en) 2008-06-12
CN101573328B (zh) 2014-04-02
US20080249031A1 (en) 2008-10-09
CN101573328A (zh) 2009-11-04
DK2091910T3 (en) 2014-12-01
CN103951583A (zh) 2014-07-30
CN103951583B (zh) 2016-01-06
PT2091910E (pt) 2014-11-18
PL2091910T3 (pl) 2015-02-27
PA8759501A1 (es) 2009-04-23
HK1199885A1 (en) 2015-07-24
MX2009006055A (es) 2009-06-16
CA2669849C (en) 2012-01-31
IL198732A (en) 2014-02-27
KR20090080113A (ko) 2009-07-23
JP2010511689A (ja) 2010-04-15
NO20091892L (no) 2009-06-17
AU2007330478A1 (en) 2008-06-12
TW200833319A (en) 2008-08-16
IL198732A0 (en) 2010-02-17
AU2007330478B2 (en) 2011-09-08
HN2007000536A (es) 2011-01-17
CA2669849A1 (en) 2008-06-12
CN103923169B (zh) 2017-05-24
UY30758A1 (es) 2008-07-31
CN103923169A (zh) 2014-07-16
EP2091910B1 (en) 2014-08-20
NO338908B1 (no) 2016-10-31
AR064809A1 (es) 2009-04-29
JP5495787B2 (ja) 2014-05-21
ES2524021T3 (es) 2014-12-03
HK1138567A1 (en) 2010-08-27
EP2091910A1 (en) 2009-08-26
WO2008068615A8 (en) 2009-05-28
HK1200440A1 (zh) 2015-08-07
TWI345466B (en) 2011-07-21
KR101125932B1 (ko) 2012-03-22
US7692038B2 (en) 2010-04-06
CL2007003491A1 (es) 2008-06-20

Similar Documents

Publication Publication Date Title
PE20081251A1 (es) Formas cristalinas del acido (3s)-3-[n-(n'-(2-terc-butilfenil)oxamil)alaninil]amino-5-(2',3',5',6'-tetrafluorofenoxi)-4-oxopentanoico
UY29611A1 (es) Modificaciones cristalinas de piraclostrobina
ECSP088184A (es) Derivados de benzoquinazolina y su uso en el tratamiento de enfermedades óseas
UY31870A (es) Receptor metabotrópico de glutamato potenciadores 286
UY29856A1 (es) Forma cristalina 8d del clorhidrato de la ivabradina, su procedimiento de preparación, y las composiciones farmaceuticas que la contienen
CR8246A (es) Forma cristalina gamma-d del clorhidrato de ivabradina, su procedimiento de preparacion y composiciones farmaceuticas que las contienen
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
SV2008003088A (es) Nueva forma cristalina vi de la agomelatina, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen
ECSP066375A (es) Forma cristalina gamma de clorhidrato de ivabradina, su procedimiento de preparación y composiciones farmacéuticas que la contienen
UY30500A1 (es) Compuestos de azabencimidazolilo
PA8791801A1 (es) Compuestos de pirazol
ECSP088082A (es) Derivados de piridazina
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
UY31524A1 (es) Nuevos compuestos 010
ECSP077275A (es) Novedosos derivados de heteroarilsulfamida benzofusionados utiles como agentes anticonvulsivos
UY31164A1 (es) Nuevos derivados de bencimidazol, composiciones farmacéuticas conteniéndolos y aplicaciones
AR059596A1 (es) Formas cristalinas anhidras y solvatadas de n-(benzo[b]tien-3-ilmetil)sulfamida.
UY35182A (es) ?COMPUESTOS DE HEXAHIDROPIRANO[ 3,4-d][1,3]TIAZIN-2-AMINA? .
CR11452A (es) 5-((3,3,3-trifluoro-2-hidroxi-1-arilpropil)amino)-1h-quinolin-2-onas, un proceso para su produccion y su uso como agentes antiflamatorios
CO6660435A2 (es) Una forma cristalina de clorhidrato de (r) -7- cloro-n- (quinuclidin -3-il)benzo[b] tiofeno-2- carboxamida monohodratado
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
CO6321280A2 (es) Nueva clase espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
ECSP099506A (es) Derivados de 2-quinolinona y 2 quinoxalinona y su utilización como agentes anti bacterianos
AR024494A1 (es) Proceso para la preparacion de derivados de ciclopentano sustituido y novedosas estructuras cristalinas de los mismos
UY29804A1 (es) Quinolinas de alquilnitrilo

Legal Events

Date Code Title Description
FD Application declared void or lapsed